Smoked cannabis produces different acute effects by use frequency, with sex modifying the signal in unexpected ways
A randomized, double-blind, placebo-controlled crossover trial is adding human data to a question that has long been dominated by animal work: do women respond more strongly than men to THC, or does recent use matter more than sex once real-world smoking patterns are taken into account? In 44 adults, including 22 females, investigators compared three smoked cannabis conditions — 0% THC, 4% THC, and 10% THC — while measuring blood THC and metabolites, subjective drug effects, mood, and self-administration behavior.
The acute pharmacology was straightforward. Active cannabis increased subjective effects and raised plasma THC and metabolite levels relative to placebo. The behavioral signal was more revealing: a frequency-by-strength interaction emerged in exploratory follow-up, and the frequent-use group showed larger increases in misuse-related ratings, including “Like” and “Take again,” than the occasional-use group. Frequent users also self-administered more cannabis. Sex did not modify that pattern.
One result ran against the prevailing expectation from preclinical work and several human laboratory studies.
Frequent use, not sex alone, tracked with stronger reinforcement-related responses
The trial was designed around two variables that matter clinically but are often examined in isolation: sex and cannabis-use frequency. Participants were grouped by use frequency as either more than four days per week or four days per week or less, with balance across sex. That design matters because tolerance is not an abstract pharmacology concept; it can shift both the perceived reward from cannabis and the likelihood that a person keeps using when intoxication is already familiar.
Among frequent users, the subjective pull of cannabis was stronger. Ratings tied to misuse liability, especially “Like” and “Take again,” climbed more steeply after active cannabis than after placebo, and the self-administration task echoed that finding. In bedside terms, people who use cannabis more often may be the group most likely to keep choosing it when given the option, even if they no longer describe the same degree of intoxication as occasional users.
The trial also found that THC and its metabolites tended to be highest in frequent-use males. That pattern points toward pharmacokinetic differences as a possible contributor to tolerance and escalation, even though the study was not built to prove a mechanism. Faster or larger systemic exposure can alter the timing and intensity of the central nervous system effect, and repeated exposure can blunt the subjective impact of a given dose. For smoked cannabis, where delivery is rapid and variable, those differences can be especially important.
Occasional-use males reported stronger intoxication and impairment at active doses
The sex-specific findings were not uniform across the sample. Ratings of “High,” sedation or impairment, dysphoric arousal, and “Bad effect” were higher at active strengths for occasional-use males relative to sex- and frequency-matched counterparts. Those results emerged through exploratory follow-up and should be read cautiously, but they are still clinically interesting because they complicate the familiar narrative that females are always more sensitive to the acute effects of THC.
Human laboratory cannabis studies have often suggested greater female sensitivity to intoxication at lower doses or under certain routes of administration. This trial did not reproduce that simple pattern. Instead, the acute response appeared to depend on how often participants used cannabis, with sex becoming more relevant in some subsets than in the full cohort. The practical implication is direct: a person’s recent cannabis exposure may be as important as sex when estimating how strongly smoked THC will alter mood, impairment, or reinforcement.
The frequency signal also fits with the biology of tolerance. Repeated activation of cannabinoid receptor 1 pathways can reduce the intensity of subjective intoxication while preserving or even amplifying the learned value of the drug. In that setting, a frequent user may report less dramatic “high” or impairment than an occasional user, yet still show stronger drug-seeking behavior when cannabis is available. That mismatch is exactly the kind of profile that can feed escalation and cannabis use disorder risk.
Plasma THC patterns point toward exposure thresholds worth testing in future studies
The authors frame the findings as a challenge to earlier evidence of greater cannabis sensitivity among females and as a reason to look more closely at exposure thresholds for tolerance development and escalation. The wording is careful, and it should be. This study was small, exploratory in its interaction analyses, and limited to acute effects after smoked cannabis. Still, the data point in a clinically useful direction: sex may influence acute cannabis response, but frequency of use can reshape the whole dose-response relationship.
That is especially relevant for smoked cannabis, where dose is notoriously difficult to standardize outside the laboratory. A 4% or 10% product does not translate neatly into a fixed systemic exposure, and the blood measurements in this trial underscore that the same nominal strength can produce different pharmacokinetic profiles across users. If frequent-use males tend to accumulate higher THC and metabolite levels, future work should ask whether that pattern predicts tolerance trajectories, escalation, or risk for cannabis use disorder more reliably than sex alone.
For clinicians, the take-home is practical even without a treatment algorithm attached to it. Counseling about cannabis cannot assume that sex determines sensitivity in a simple direction. Frequency of use, prior exposure, and the reinforcing pull of the drug appear to be tightly linked, and those factors may help explain why some users escalate while others remain occasional consumers despite similar access to cannabis.
The study does not settle the question of why women have sometimes appeared more sensitive in other human trials. It does, however, show that acute smoked cannabis effects are not governed by sex in isolation. The next step is to define whether exposure thresholds, route of administration, and cumulative use history explain the divergence between laboratory findings and preclinical expectations — and whether those same variables predict who crosses from use to disorder.